论文部分内容阅读
目的评价阿法骨化醇软胶囊对慢性阻塞性肺疾病(COPD)患者免疫功能的影响。方法入选172例COPD患者,随机分成试验组86例和对照组86例,2组常规治疗相同(包括戒烟、支气管扩张剂、祛痰剂等),试验组口服阿法骨化醇软胶囊0.25μg,1天1次,治疗时间为6个月,比较2组治疗前后免疫功能(CD3+、CD4+、CD8+和CD4+/CD8+)、肺功能[用力肺活量(FVC)、第l秒用力呼气容积(FEV1)、FEV1/FVC、肺一氧化碳弥散量/肺泡容积(DLC0/VA)]及随访半年COPD急性发作情况。结果治疗后,试验组CD3+、CD4+、CD8+和CD4+/CD8+均较治疗前和对照组显著升高;治疗后,试验组FEV1、FEV1/FVC、DLCO/VA均显著高于治疗前和对照组(P<0.05)。对照组治疗前后CD3+、CD4+、CD8+、CD4+/CD8+、FEV1、FEV1/FVC、DLCO/VA比较,差异无统计学意义(P>0.05)。试验组6个月内COPD急性加重的发生率(9.30%)显著低于对照组(25.58%)(P<0.05)。结论阿法骨化醇软胶囊可通过改善COPD患者免疫功能来改善肺功能,降低急性发作次数。
Objective To evaluate the effect of alfacalcidol soft capsule on immune function in patients with chronic obstructive pulmonary disease (COPD). Methods A total of 172 patients with COPD were enrolled and randomly divided into experimental group (86 cases) and control group (86 cases). The two groups were treated routinely (including smoking cessation, bronchodilator and expectorants). The experimental group was given oral alfacalol soft capsule , Once a day for 6 months. The immune function (CD3 +, CD4 +, CD8 + and CD4 + / CD8 +), pulmonary function (FVC), forced expiratory volume at 1 second ), FEV1 / FVC, diffuse pulmonary carbon monoxide / alveolar volume (DLC0 / VA) and follow-up of six months of acute exacerbation of COPD. Results After treatment, the levels of CD3 +, CD4 +, CD8 + and CD4 + / CD8 + in the experimental group were significantly higher than those before treatment and in the control group. After treatment, FEV1, FEV1 / FVC and DLCO / VA in the experimental group were significantly higher than those before treatment and in the control group P <0.05). The difference of CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, FEV1, FEV1 / FVC and DLCO / VA before and after treatment in the control group was not statistically significant (P> 0.05). The incidence of acute exacerbation of COPD (9.30%) in the experimental group within 6 months was significantly lower than that in the control group (25.58%) (P <0.05). Conclusion Alfacalciferol soft capsule can improve pulmonary function and reduce the number of acute attacks by improving immune function in COPD patients.